Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
about
Antiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsAntiviral medications for preventing cytomegalovirus disease in solid organ transplant recipientsPre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipientsHuman cytomegalovirus resistance to antiviral drugsClinical utility of viral load in management of cytomegalovirus infection after solid organ transplantationProspective evaluation of the clinical utility of different methods for the detection of human cytomegalovirus disease after liver transplantation.Changing impact of cytomegalovirus in liver transplantation -- a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis.Management of cytomegalovirus infection and disease in liver transplant recipients.Current concepts on cytomegalovirus infection after liver transplantationThe impact of human herpesvirus-6 and -7 infection on the outcome of liver transplantation.Homozygosity for the toll-like receptor 2 R753Q single-nucleotide polymorphism is a risk factor for cytomegalovirus disease after liver transplantation.Valganciclovir for the prevention and treatment of cytomegalovirus disease in immunocompromised hosts.Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report.Two strategies for prevention of cytomegalovirus infections after liver transplantation.Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review of the literature.Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovirOral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections.A retrospective study of cytomegalovirus pneumonia in renal transplant patients.Strategies for managing cytomegalovirus in transplant recipients.Universal prophylaxis or preemptive strategy for cytomegalovirus disease after liver transplantation: a systematic review and meta-analysis.Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid-organ-transplant recipients by use of a real-time PCR assayIs cytomegalovirus infection dangerous in cytomegalovirus-seropositive recipients after liver transplantation?Cytomegalovirus Infection in Liver Transplant Recipients: Current Approach to Diagnosis and Management.Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation.Treatment of alpha and beta herpesvirus infections in solid organ transplant recipients.Cryptogenic colitis due to occult cytomegalovirus infection.Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients.Comparison of quantitation of cytomegalovirus DNA by real-time PCR in whole blood with the cytomegalovirus antigenemia assay.A direct and indirect comparison meta-analysis on the efficacy of cytomegalovirus preventive strategies in solid organ transplant.Cytomegalovirus infection after liver transplantation: current concepts and challenges.The pathogenesis of hepatitis C virus is influenced by cytomegalovirus.Prophylaxis versus preemptive therapy for cytomegalovirus disease in high-risk liver transplant recipients.Preemptive strategy for ganciclovir administration against cytomegalovirus in liver transplantation recipients.Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients.The CARI guidelines. CMV disease and kidney transplant: pre-emptive treatment of cytomegalovirus.Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.Valganciclovir as treatment for cytomegalovirus disease in solid organ transplant recipients.It's not too late: a proposal to standardize the terminology of "late-onset" cytomegalovirus infection and disease in solid organ transplant recipients.
P2860
Q24200697-40E9E4E4-F796-49CD-8466-7DB30AC37692Q24200991-F3D9D429-1E38-4A1C-BF8A-B15E24C0BFADQ24243124-86228EF7-97FF-4725-9A25-5BA096A7C5C8Q24244606-CA0D081D-52AB-4F98-B02F-AF39581D3BECQ24556634-72D11223-BCE5-4843-BA63-B129F2C4AD44Q26826856-23E2ECFF-D796-45AC-A9F9-41E5B600507CQ33205085-89DCD3F8-F8C8-4ECC-A017-17D0F2D2332EQ33218675-570BD021-8583-4152-9D38-66F2FD7F067CQ33845124-EFED132D-9D1B-4704-BB3A-885CA7035B1FQ34390310-0719D75E-0FEA-4C95-BDB7-0EDF7196087DQ34768066-B7D9963A-9314-4BD5-A4E4-0748FEEA12E0Q35694674-5D36AE81-7F61-465D-9313-BCF69F2C7DAEQ35917319-28C2414E-8F75-4F2D-85D6-05490F0BF0F1Q36006091-6F7B47FB-699E-4B52-802A-1F497A352D29Q36724385-02C7F0B6-B907-43C8-8295-92C5DE2921E5Q37034498-72385DAB-B526-476B-8107-EBDBBB2BD09EQ37488882-F78FC67C-4150-4CC9-B5FC-86BA342D1AA2Q37624896-7593742B-915C-476E-BB87-0F1CD6BF09CDQ37710083-697757A2-26DF-4DBD-ADC6-E4E4EC8F3303Q37773992-F797BCA2-1365-4448-A290-89A594D3308AQ38293175-25026166-0B4D-4DBE-B7A8-30BADED65034Q38359566-863BF8AD-1F7A-4578-A4BB-EF9D85F825F2Q38475761-63BFE54B-7194-42FE-8D29-1383E1023F96Q39405795-1171ECAE-C005-471F-A4E2-E15C2C934519Q40115981-EEF71FFE-5AAD-4133-AAAE-1E432DDE24A5Q40426465-E3427C5E-39A2-4FE8-AF64-7E208D8AD630Q41060045-ED82DCF2-1FBF-41F3-8FED-B4B48B1F2293Q41500588-35BAEF87-2990-4C2C-B7BD-A557ED4F87C9Q41566881-F26541EA-6BBC-45F6-BCBE-EB2084D0AFA7Q42234413-B968EC61-9AE8-4489-BB46-2D3C1BE7569DQ42549311-6E3374BB-A233-4282-9BAF-AD87447AD45BQ43040318-9B753166-559A-4CA0-A2E6-8E0BD5E20243Q44100013-376DEA79-6667-42B2-B1B5-D441FBAEF6F5Q44249073-E8E2CE72-C1DA-454B-8722-3DC712A27080Q44800855-6BAEAC9B-ACD8-453A-B337-AB10C42AFA01Q44867947-EAC4EEB6-B524-4369-8DB8-4F935E910CB8Q46692829-7B1564DE-9620-4CBF-9448-221BE945E364Q46826218-4999BF5C-97C1-446D-9EBF-B1CC0B43EC9EQ50910864-C73E4828-FF0E-47FF-9D6E-13E99AA85117
P2860
Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@en
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@nl
type
label
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@en
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@nl
prefLabel
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@en
Preemptive use of oral gancicl ...... zed, placebo-controlled trial.
@nl
P2093
P356
P1476
Preemptive use of oral gancicl ...... ized, placebo-controlled trial
@en
P2093
Carlos V Paya
Greg Jenkins
Irene G Sia
Jennie A Wilson
Mark J Espy
Michael J DeBernardi
Robin Patel
Russell H Wiesner
Thomas F Smith
William S Harmsen
P304
P356
10.1086/339449
P407
P577
2002-03-19T00:00:00Z